Headquartered in Chicago, IL Fiscal year ends December NASDAQ: XERS xerispharma.com
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a biopharmaceutical company focused on developing and commercializing innovative therapies across endocrinology and related therapeutic areas. The company has three commercially available products: Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome, Gvoke (ready-to-use liquid glucagon) for the treatment of severe hypoglycemia, and Keveyis (dichlorphenamide) for primary periodic paralysis. Xeris also has a development pipeline led by XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine injection for hypothyroidism. The company leverages its proprietary XeriSol and XeriJect formulation technology platforms for both internal programs and partnerships. Revenue growth is currently driven by rapid adoption of Recorlev, which has become the company's largest product by revenue. Updated
Are you interested in investing in penny stocks? Though doing so does come with risk, making the right investment decisions in the penny stock category can produce eye-opening returns. While the profits…
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a biopharmaceutical company focused on developing and commercializing innovative therapies across endocrinology and related therapeutic areas.
The Wall Street consensus 12-month price target for XERS is $12.86.
